Monday , March 30 2020
Home / argentina / Bronchiolitis: an experimental vaccine with Argentine pregnant women is successfully tested

Bronchiolitis: an experimental vaccine with Argentine pregnant women is successfully tested



[ad_1]

A vaccine against the bronchiolitisThat would apply to mothers to pass the antibodies to their children via the placental route, it was tested with good answers in pregnant women in some countries, including the ArgentinaThey reported the local doctors who participated in the investigation.

While there are several teams of scientists working to develop a vaccine against the world respiratory syncytial virus (VRS)What causes bronchiolitis, the particularity of this research, which is in its final stage, is that it would apply to mothers to protect babies especially during the first three months of life, when the disease can to be more severe.

"Because the VRS does not vary, as is the case with the flu, which requires a new vaccination every year, with this vaccine the boys would be immunized at birth and for the first months of life, Which is when they need more protection, "they highlighted from the Infant Foundation, an NGO created by Argentine doctors studying the causes of respiratory diseases in boys and participating in the investigation into the new dose.

How were the tests?

The vaccine was recently administered to 40 pregnant women attending the Military Hospital in Buenos Aires and more than 200 in Tucumán and Salta, and the results were "excellent". "It was given to pregnant women to see if antibodies were passed to infants, who have not yet developed a good immune response," explained the healthcare deputy director of the Matern Infantil Department of this port health center, Gonzalo Pérez Marc (MN). 110,813).

The specialist said that in the 40 pregnant women who participated in the city of Buenos Aires "the generation of antibodies was excellent".

"Now we have to keep track of the guys and wait for the assessment of regulatory bodies in the world, for at least a few years, and then see if, to meet the protection goals, can be added to the vaccine calendar"Perez completed Marc.

For his part Fernando Polack (MN 83,428), director of Infant, has indicated that "There is no specific treatment for this disease at the moment"." The research for a bronchitis vaccine, from which they participate in the final assessment phase in Argentina, the United States, New Zealand, the Philippines and South Africa, is very advanced, "he said. added

The main respiratory infection in children under two

Ángela Gentile (MN 49908), chief of Epidemiology at the Children's Hospital Ricardo Gutiérrez and former president of the Sociedad Argentina de Pediatría (SAP), pointed out that "although two thirds of those under the age of two could be See affected by this virus, the condition does not attack everyone alike. " "We are worried about the most vulnerable guys, that is, preterm infants with low weight or with certain lung conditions For having received mechanical ventilation for a long time, as well as children with congenital heart disease. This population has between four and five times more risk of hospitalization for VRS infection than healthy children, "he warned.

In Argentina, the annual peak of the disease, which It begins with a cold and after two or three days it has symptoms such as wheezing, fatigue, fever or sore throat when breathing occurs between May and August. This is the main respiratory infection in children under two and the first cause of death in children between one month and one year. According to the Secretary of Health of the Nation, during 2017 283,828 registered cases took place 226,835 until the week 46 of 2018.

Also, statistics from the 2016 Society of Pediatrics of 2016 showed that 740 children under the age of two had died of bronchiolitis.

Regarding the current prevention, the only approved intervention against severe disease for VRS is the administration of an antibody directed to a very specific population (Premature babies with high risk cardiomyopathy) and have a high cost. The route of infection is through direct contact with contaminated hands with nasal secretion, cough or sneezing of an infected person.

[ad_2]
Source link